BRUSSELS, Sept 3 (Reuters) - U.S. gene sequencing company Illumina (ILMN.O), opens new tab on Tuesday won its court fight against the European Union's investigation ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

After hours: September 19 at 7:59 PM EDT ...

A top court in the EU on Tuesday ruled against the European Commission's decision to review Illumina's (NASDAQ:ILMN) 2021 acquisition of cancer test developer Grail (NASDAQ:GRAL), eliminating the ...

Though Illumina said goodbye to Grail this past summer—after butting heads for years with antitrust regulators and activist investors, while enduring heavy fines and orders to split—the ...

(RTTNews) - Illumina, Inc. (ILMN) Tuesday announced that the 432 million euros fine imposed by the European Commission over GRAIL deal is no longer be payable after favorable verdict by the ...

(Bloomberg) -- Illumina Inc.’s blocked $7 billion takeover of cancer-detection provider Grail Inc. should never have been probed by the European Union, according to a top court ruling that ...

Gene sequencing company Illumina took a legal gamble in the summer of 2021, closing on its purchase of Grail, a former business unit it spun off in 2016, before European competition regulators had ...